secwatch.observer — SEC 8-K summary
======================================

Issuer:     Kyverna Therapeutics, Inc. (KYTX)
CIK:        0001994702
Form:       8-K
Filed at:   2026-05-18T12:00:16+00:00
Accession:  0001193125-26-227920
Event type: leadership
Sentiment:  neutral
Materiality: 0.70
Item codes: 5.02, 8.01, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Kyverna appoints Greg Martini as CFO; Marc Grasso transitions to strategic advisor
--------------------------------------------------------------------------------

- Greg Martini named CFO effective May 18, 2026; previously CFO of Ironwood Pharmaceuticals.
- Marc Grasso steps down as CFO, stays as strategic advisor through Aug 1, 2026 for transition.
- Compensation: $525K salary, 40% bonus target, $300K sign-on bonus, 325K stock option (4-year vest).
- Company advancing miv-cel (KYV-101) toward potential first approval in stiff person syndrome.
- Option grant of 325K shares as inducement under Nasdaq Rule 5635(c)(4); exercise price May 18 close.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1994702/000119312526227920/0001193125-26-227920-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1994702/000119312526227920/kytx-20260514.htm
  HTML page:      https://secwatch.observer/filing/0001193125-26-227920

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer